Allergy Therapeutics (LON:AGY) Shares Down 10.4% - Here's What Happened

Allergy Therapeutics plc (LON:AGY - Get Free Report) shares dropped 10.4% on Monday . The stock traded as low as GBX 5.62 ($0.07) and last traded at GBX 6.28 ($0.08). Approximately 180,738 shares changed hands during trading, a decline of 66% from the average daily volume of 535,030 shares. The stock had previously closed at GBX 7 ($0.09).

Allergy Therapeutics Price Performance

The stock has a market capitalization of £286.20 million, a P/E ratio of -100.00, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The business's 50 day simple moving average is GBX 6.60 and its two-hundred day simple moving average is GBX 5.43. The company has a quick ratio of 1.48, a current ratio of 1.40 and a debt-to-equity ratio of 37.22.

Allergy Therapeutics (LON:AGY - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 94.29% and a negative return on equity of 155.90%. As a group, sell-side analysts forecast that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.